|
1
|
Bray F, Laversanne M, Sung H, Ferlay J,
Siegel RL, Soerjomataram I and Jemal A: Global cancer statistics
2022: GLOBOCAN estimates of incidence and mortality worldwide for
36 cancers in 185 countries. CA Cancer J Clin. 74:229–263.
2024.PubMed/NCBI
|
|
2
|
Zhu B, Gu H, Mao Z, Beeraka NM, Zhao X,
Anand MP, Zheng Y, Zhao R, Li S, Manogaran P, et al: Global burden
of gynaecological cancers in 2022 and projections to 2050. J Glob
Health. 14:041552024. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Chen MQ, Gong MQ, Gao HC and Gao XM:
Gynecologic cancers in a hospital: A retrospective analysis of
admission data over ten years. Sichuan Da Xue Xue Bao Yi Xue Ban.
46:326–330. 2015.(In Chinese). PubMed/NCBI
|
|
4
|
Huang Z, Zheng Y, Wen W, Wu C, Bao P, Wang
C, Zhong W, Gao YT, Jin F, Xiang YB, et al: Incidence and mortality
of gynaecological cancers: Secular trends in urban Shanghai, China
over 40 years. Eur J Cancer. 63:1–10. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Wang Z, Guo E, Yang B, Xiao R, Lu F, You L
and Chen G: Trends and age-period-cohort effects on mortality of
the three major gynecologic cancers in China from 1990 to 2019:
Cervical, ovarian and uterine cancer. Gynecol Oncol. 163:358–363.
2021. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Holcakova J, Bartosik M, Anton M, Minar L,
Hausnerova J, Bednarikova M, Weinberger V and Hrstka R: New trends
in the detection of gynecological precancerous lesions and
early-stage cancers. Cancers (Basel). 13:63392021. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Kohn EC, Mills GB and Liotta L: Promising
directions for the diagnosis and management of gynecological
cancers. Int J Gynaecol Obstet. 83 (Suppl 1):S203–S209. 2003.
View Article : Google Scholar
|
|
8
|
Akter S, Rahman MA, Hasan MN, Akhter H,
Noor P, Islam R, Shin Y, Rahman MDH, Gazi MS, Huda MN, et al:
Recent advances in ovarian cancer: Therapeutic strategies,
potential biomarkers, and technological improvements. Cells.
11:6502022. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Palioura D, Lazou A and Drosatos K:
Kruppel-like factor (KLF)5: An emerging foe of cardiovascular
health. J Mol Cell Cardiol. 163:56–66. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Kinisu M, Choi YJ, Cattoglio C, Liu K,
Roux de Bezieux H, Valbuena R, Pum N, Dudoit S, Huang H, Xuan Z, et
al: Klf5 establishes bi-potential cell fate by dual regulation of
ICM and TE specification genes. Cell Rep. 37:1099822021. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Dong JT and Chen C: Essential role of KLF5
transcription factor in cell proliferation and differentiation and
its implications for human diseases. Cell Mol Life Sci.
66:2691–2706. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhao D, Zheng HQ, Zhou Z and Chen C: The
Fbw7 tumor suppressor targets KLF5 for ubiquitin-mediated
degradation and suppresses breast cell proliferation. Cancer Res.
70:4728–4738. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zhi X and Chen C: WWP1: A versatile
ubiquitin E3 ligase in signaling and diseases. Cell Mol Life Sci.
69:1425–1434. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Du JX, Bialkowska AB, McConnell BB and
Yang VW: SUMOylation regulates nuclear localization of Krüppel-like
factor 5. J Biol Chem. 283:31991–32002. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang X, Choi PS, Francis JM, Gao GF,
Campbell JD, Ramachandran A, Mitsuishi Y, Ha G, Shih J, Vazquez F,
et al: Somatic superenhancer duplications and hotspot mutations
lead to oncogenic activation of the KLF5 transcription factor.
Cancer Discov. 8:108–125. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chen C, Benjamin MS, Sun X, Otto KB, Guo
P, Dong XY, Bao Y, Zhou Z, Cheng X, Simons JW and Dong JT: KLF5
promotes cell proliferation and tumorigenesis through gene
regulation and the TSU-Pr1 human bladder cancer cell line. Int J
Cancer. 118:1346–1355. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Pattison JM, Posternak V and Cole MD:
Transcription factor KLF5 binds a cyclin E1 polymorphic intronic
enhancer to confer increased bladder cancer risk. Mol Cancer Res.
14:1078–1086. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Luo Y and Chen C: The roles and regulation
of the KLF5 transcription factor in cancers. Cancer Sci.
112:2097–2117. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Diakiw SM, Kok CH, To LB, Lewis ID, Brown
AL and D'Andrea RJ: The granulocyte-associated transcription factor
Krüppel-like factor 5 is silenced by hypermethylation in acute
myeloid leukemia. Leuk Res. 36:110–116. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Fu RJ, He W, Wang XB, Li L, Zhao HB, Liu
XY, Pang Z, Chen GQ, Huang L and Zhao KW: DNMT1-maintained
hypermethylation of Krüppel-like factor 5 involves in the
progression of clear cell renal cell carcinoma. Cell Death Dis.
8:e29522017. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Chen CH, Yang N, Zhang Y, Ding J, Zhang W,
Liu R, Liu W and Chen C: Inhibition of super enhancer downregulates
the expression of KLF5 in basal-like breast cancers. Int J Biol
Sci. 15:1733–1742. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liao Q, Chen L, Zhang N, Xi Y, Hu S, Ng
DM, Ahmed FYH, Zhao G, Fan X, Xie Y, et al: Network analysis of
KLF5 targets showing the potential oncogenic role of SNHG12 in
colorectal cancer. Cancer Cell Int. 20:4392020. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Cheng Z, Liu G, Huang C and Zhao X: KLF5
activates lncRNA DANCR and inhibits cancer cell autophagy
accelerating gastric cancer progression. NPJ Genom Med. 6:752021.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu R, Shi P, Nie Z, Liang H, Zhou Z, Chen
W, Chen H, Dong C, Yang R, Liu S and Chen C: Mifepristone
suppresses basal triple-negative breast cancer stem cells by
down-regulating KLF5 expression. Theranostics. 6:533–544. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Zhou W, Song F, Wu Q, Liu R, Wang L, Liu
C, Peng Y, Mao S, Feng J and Chen C: miR-217 inhibits
triple-negative breast cancer cell growth, migration, and invasion
through targeting KLF5. PLoS One. 12:e01763952017. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Zhou T, Chen S and Mao X: miR-145-5p
affects the differentiation of gastric cancer by targeting KLF5
directly. J Cell Physiol. 234:7634–7644. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shan TD, Tian ZB, Li Q, Jiang YP, Liu FG,
Sun XG, Han Y, Sun LJ and Chen L: Long intergenic noncoding RNA
00908 promotes proliferation and inhibits apoptosis of colorectal
cancer cells by regulating KLF5 expression. J Cell Physiol.
236:889–899. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yu L, Xu Q, Yu W, Duan J and Dai G: LncRNA
cancer susceptibility candidate 15 accelerates the breast cancer
cells progression via miR-153-3p/KLF5 positive feedback loop.
Biochem Biophys Res Commun. 506:819–825. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang C, Zheng J, Xue Y, Yu H, Liu X, Ma J,
Liu L, Wang P, Li Z, Cai H and Liu Y: The effect of
MCM3AP-AS1/miR-211/KLF5/AGGF1 axis regulating glioblastoma
angiogenesis. Front Mol Neurosci. 10:4372018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Z and Teng CT: Phosphorylation of
Kruppel-like factor 5 (KLF5/IKLF) at the CBP interaction region
enhances its transactivation function. Nucleic Acids Res.
31:2196–2208. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
He M, Han M, Zheng B, Shu YN and Wen JK:
Angiotensin II stimulates KLF5 phosphorylation and its interaction
with c-Jun leading to suppression of p21 expression in vascular
smooth muscle cells. J Biochem. 146:683–691. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang XH, Zheng B, Han M, Miao SB and Wen
JK: Synthetic retinoid Am80 inhibits interaction of KLF5 with RAR
alpha through inducing KLF5 dephosphorylation mediated by the
PI3K/Akt signaling in vascular smooth muscle cells. FEBS Lett.
583:1231–1236. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guo P, Zhao KW, Dong XY, Sun X and Dong
JT: Acetylation of KLF5 alters the assembly of p15 transcription
factors in transforming growth factor-beta-mediated induction in
epithelial cells. J Biol Chem. 284:18184–18193. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhao C, Li Y, Qiu W, He F, Zhang W, Zhao
D, Zhang Z, Zhang E, Ma P, Liu Y, et al: C5a induces A549 cell
proliferation of non-small cell lung cancer via GDF15 gene
activation mediated by GCN5-dependent KLF5 acetylation. Oncogene.
37:4821–4837. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tao R, Zhang B, Li Y, King JL, Tian R, Xia
S, Schiavon CR and Dong JT: HDAC-mediated deacetylation of KLF5
associates with its proteasomal degradation. Biochem Biophys Res
Commun. 500:777–782. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huang Y, Xu Y, Feng S, He P, Sheng B and
Ni J: miR-19b enhances osteogenic differentiation of mesenchymal
stem cells and promotes fracture healing through the
WWP1/Smurf2-mediated KLF5/β-catenin signaling pathway. Exp Mol Med.
53:973–985. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Qin J, Zhou Z, Chen W, Wang C, Zhang H, Ge
G, Shao M, You D, Fan Z, Xia H, et al: BAP1 promotes breast cancer
cell proliferation and metastasis by deubiquitinating KLF5. Nat
Commun. 6:84712015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Wu Y, Qin J, Li F, Yang C, Li Z, Zhou Z,
Zhang H, Li Y, Wang X, Liu R, et al: USP3 promotes breast cancer
cell proliferation by deubiquitinating KLF5. J Biol Chem.
294:17837–17847. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Zhi X, Zhao D, Zhou Z, Liu R and Chen C:
YAP promotes breast cell proliferation and survival partially
through stabilizing the KLF5 transcription factor. Am J Pathol.
180:2452–2461. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Zhao D, Zhi X, Zhou Z and Chen C: TAZ
antagonizes the WWP1-mediated KLF5 degradation and promotes breast
cell proliferation and tumorigenesis. Carcinogenesis. 33:59–67.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Burmeister CA, Khan SF, Schäfer G, Mbatani
N, Adams T, Moodley J and Prince S: Cervical cancer therapies:
Current challenges and future perspectives. Tumour Virus Res.
13:2002382022. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ferrall L, Lin KY, Roden RBS, Hung CF and
Wu TC: Cervical cancer immunotherapy: Facts and hopes. Clin Cancer
Res. 27:4953–4973. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Das S, Babu A, Medha T, Ramanathan G,
Mukherjee AG, Wanjari UR, Murali R, Kannampuzha S, Gopalakrishnan
AV, Renu K, et al: Molecular mechanisms augmenting resistance to
current therapies in clinics among cervical cancer patients. Med
Oncol. 40:1492023. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Gennigens C, Jerusalem G, Lapaille L, De
Cuypere M, Streel S, Kridelka F and Ray-Coquard I: Recurrent or
primary metastatic cervical cancer: Current and future treatments.
ESMO Open. 7:1005792022. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Polten R, Kutle I, Hachenberg J, Klapdor
R, Morgan M and Schambach A: Towards novel gene and cell therapy
approaches for cervical cancer. Cancers (Basel). 15:2632022.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Liu L, Wang M, Li X, Yin S and Wang B: An
overview of novel agents for cervical cancer treatment by inducing
apoptosis: Emerging drugs ongoing clinical trials and preclinical
studies. Front Med (Lausanne). 8:6823662021. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sun Q, Wang L, Zhang C, Hong Z and Han Z:
Cervical cancer heterogeneity: A constant battle against viruses
and drugs. Biomark Res. 10:852022. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Sharma S, Deep A and Sharma AK: Current
treatment for cervical cancer: An update. Anticancer Agents Med
Chem. 20:1768–1779. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Marrero-Rodríguez D, Taniguchi-Ponciano K,
Jimenez-Vega F, Romero-Morelos P, Mendoza-Rodríguez M, Mantilla A,
Rodriguez-Esquivel M, Hernandez D, Hernandez A, Gomez-Gutierrez G,
et al: Krüppel-like factor 5 as potential molecular marker in
cervical cancer and the KLF family profile expression. Tumor Biol.
35:11399–11407. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Marrero-Rodríguez D, la Cruz HAD,
Taniguchi-Ponciano K, Gomez-Virgilio L, Huerta-Padilla V,
Ponce-Navarrete G, Andonegui-Elguera S, Jimenez-Vega F,
Romero-Morelos P, Rodriguez-Esquivel M, et al: Krüppel like factors
family expression in cervical cancer cells. Arch Med Res.
48:314–322. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Zhang H, Lu Y, Wang S, Sheng X and Zhang
S: MicroRNA-152 Acts as a tumor suppressor MicroRNA by inhibiting
krüppel-like factor 5 in human cervical cancer. Oncol Res.
27:335–340. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Cao H, Pan G, Tang S, Zhong N, Liu H, Zhou
H, Peng Q and Zou Y: miR-145-5p regulates the proliferation,
migration and invasion in cervical carcinoma by targeting KLF5.
Onco Targets Ther. 13:2369–2376. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Ma D, Chang LY, Zhao S, Zhao JJ, Xiong YJ,
Cao FY, Yuan L, Zhang Q, Wang XY, Geng ML, et al: KLF5 promotes
cervical cancer proliferation, migration and invasion in a manner
partly dependent on TNFRSF11a expression. Sci Rep. 7:156832017.
View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Ma D, Pan Z, Chang Q, Zhang JJ, Liu X, Hua
N and Li GH: KLF5-mediated Eppk1 expression promotes cell
proliferation in cervical cancer via the p38 signaling pathway. BMC
Cancer. 21:3772021. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Hu C, Han Y, Zhu G, Li G and Wu X:
Krüppel-like factor 5-induced overexpression of long non-coding RNA
DANCR promotes the progression of cervical cancer via repressing
microRNA-145-3p to target ZEB1. Cell Cycle. 20:1441–1454. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Qu X, Xu C, Yang W, Li Q, Tu S and Gao C:
KLF5 inhibits the migration and invasion in cervical cancer cell
lines by regulating SNAI1. Cancer Biomark. 39:231–243. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Cao C, Xu Q, Zhu Z, Xu M, Wei Y, Lin S,
Cheng S, Zhi W, Hong P, Huang X, et al: Three-dimensional chromatin
analysis reveals Sp1 as a mediator to program and reprogram
HPV-host epigenetic architecture in cervical cancer. Cancer Lett.
588:2168092024. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Medina-Franco H: Up-to-date in ovarian
cancer. Chin Clin Oncol. 9:432020. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Hartnett EG, Knight J, Radolec M,
Buckanovich RJ, Edwards RP and Vlad AM: Immunotherapy advances for
epithelial ovarian cancer. Cancers (Basel). 12:37332020. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Ghisoni E, Imbimbo M, Zimmermann S and
Valabrega G: Ovarian cancer immunotherapy: Turning up the heat. Int
J Mol Sci. 20:29272019. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Chandra A, Pius C, Nabeel M, Nair M,
Vishwanatha JK, Ahmad S and Basha R: Ovarian cancer: Current status
and strategies for improving therapeutic outcomes. Cancer Med.
8:7018–7031. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Zheng F, Zhang Y, Chen S, Weng X, Rao Y
and Fang H: Mechanism and current progress of Poly ADP-ribose
polymerase (PARP) inhibitors in the treatment of ovarian cancer.
Biomed Pharmacother. 123:1096612020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Yang C, Xia BR, Zhang ZC, Zhang YJ, Lou G
and Jin WL: Immunotherapy for ovarian cancer: Adjuvant,
combination, and neoadjuvant. Front Immunol. 11:5778692020.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Xie H, Wang W, Xia B, Jin W and Lou G:
Therapeutic applications of PARP inhibitors in ovarian cancer.
Biomed Pharmacother. 127:1102042020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Zhu J, Yan L and Wang Q: Efficacy of
PD-1/PD-L1 inhibitors in ovarian cancer: A single-arm
meta-analysis. J Ovarian Res. 14:1122021. View Article : Google Scholar : PubMed/NCBI
|
|
66
|
Morand S, Devanaboyina M, Staats H,
Stanbery L and Nemunaitis J: Ovarian cancer immunotherapy and
personalized medicine. Int J Mol Sci. 22:65322021. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Xu L, Zou C, Zhang S, Chu TSM, Zhang Y,
Chen W, Zhao C, Yang L, Xu Z, Dong S, et al: Reshaping the systemic
tumor immune environment (STIE) and tumor immune microenvironment
(TIME) to enhance immunotherapy efficacy in solid tumors. J Hematol
Oncol. 15:872022. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Kandalaft LE, Odunsi K and Coukos G:
Immune therapy opportunities in ovarian cancer. Am Soc Clin Oncol
Educ Book. 40:1–13. 2020.PubMed/NCBI
|
|
69
|
Wang G, Yang H, Wang Y and Qin J: Ovarian
cancer targeted therapy: Current landscape and future challenges.
Front Oncol. 15:15352352025. View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Siraj AK, Pratheeshkumar P, Divya SP,
Parvathareddy SK, Alobaisi KA, Thangavel S, Siraj S, Al-Badawi IA,
Al-Dayel F and Al-Kuraya KS: Krupple-like factor 5 is a potential
therapeutic target and prognostic marker in epithelial ovarian
cancer. Front Pharmacol. 11:5988802020. View Article : Google Scholar : PubMed/NCBI
|
|
71
|
Chen X, Zhou M, Ma S, Wu H and Cai H:
KLF5-mediated CDCA5 expression promotes tumor development and
progression of epithelial ovarian carcinoma. Exp Cell Res.
429:1136452023. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wang S, Liu C, Li Y, Qiao J, Chen X, Bao
J, Li R and Xing Y: Suppression of KLF5 targets RREB1 to restrain
the proliferation of ovarian cancer cells through ERK/MAPK
signaling pathway. 3 Biotech. 15:42025. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Dong Z, Yang L and Lai D: KLF5 strengthens
drug resistance of ovarian cancer stem-like cells by regulating
survivin expression. Cell Prolif. 46:425–435. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Xiao H, Cheng G, Zhang H, Liu Y, Chen Z,
Gao Y, Gao F, Liu Y, Wang S and Kong B: Role of KLF5 in enhancing
ovarian cancer stemness and PARPi resistance: Mechanisms and
therapeutic targeting. J Transl Med. 23:4922025. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Xue Z, Li X, Zhou W and Teng Y:
KLF5-regulated ZDHHC8 reduces chemosensitivity in high-grade serous
ovarian cancer through β-catenin signaling. Sci Rep. 15:261762025.
View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Wu Y, Chen S, Shao Y, Su Y, Li Q, Wu J,
Zhu J, Wen H, Huang Y, Zheng Z, et al: KLF5 promotes tumor
progression and parp inhibitor resistance in ovarian cancer. Adv
Sci (Weinh). 10:e23046382023. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Baker-Rand H and Kitson SJ: Recent
advances in endometrial cancer prevention, early diagnosis and
treatment. Cancers (Basel). 16:10282024. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Liang B, Tan J, Li J, Wang X, Li G, Li H,
Li T and Gao H: Epidemiology, molecular typing, microbiome-immune
interactions and treatment strategies of endometrial cancer: A
review. Front Immunol. 16:15956382025. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
van den Heerik ASVM, Horeweg N, de Boer
SM, Bosse T and Creutzberg CL: Adjuvant therapy for endometrial
cancer in the era of molecular classification: Radiotherapy,
chemoradiation and novel targets for therapy. Int J Gynecol Cancer.
31:594–604. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Bruchim I, Capasso I, Polonsky A, Meisel
S, Salutari V, Werner H, Lorusso D, Scambia G and Fanfani F: New
therapeutic targets for endometrial cancer: A glimpse into the
preclinical sphere. Expert Opin Ther Targets. 28:29–43. 2024.
View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Moritake T, Kojima J, Kubota K, Terauchi
F, Isaka K and Nishi H: Kruppel-like factor 5 is upregulated and
induces cell proliferation in endometrial cancer. Oncol Lett.
21:4842021. View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Ogunmuyiwa J and Williams V: Emerging
advances in endometrial cancer: Integration of molecular
classification into staging for enhanced prognostic accuracy and
implications for racial disparities. Cancers (Basel). 16:11722024.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Viola L, Londero AP, Bertozzi S, Orsaria
M, Marzinotto S, Antoniazzi F, Renda V, Cinel J, Fruscalzo A, Lellé
RJ and Mariuzzi L: Prognostic role of Krüppel-like factors 5, 9,
and 11 in endometrial endometrioid cancer. Pathol Oncol Res.
26:2265–2272. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
84
|
Cheng TH, Thompson DJ, O'Mara TA, Painter
JN, Glubb DM, Flach S, Lewis A, French JD, Freeman-Mills L, Church
D, et al: Five endometrial cancer risk loci identified through
genome-wide association analysis. Nat Genet. 48:667–674. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
85
|
Liu T, Wang X, Zhai J, Wang Q and Zhang B:
Long noncoding RNA UCA1 facilitates endometrial cancer development
by regulating KLF5 and RXFP1 gene expressions. Cancer Biother
Radiopharm. 36:521–533. 2021.PubMed/NCBI
|
|
86
|
Chang Y, Hao M, Jia R, Zhao Y, Cai Y and
Liu Y: Metapristone (RU486-derivative) inhibits endometrial cancer
cell progress through regulating miR-492/Klf5/Nrf1 axis. Cancer
Cell Int. 21:292021. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
Wen B, Zhu R, Jin H and Zhao K:
Differential expression and role of miR-200 family in multiple
tumors. Anal Biochem. 626:1142432021. View Article : Google Scholar : PubMed/NCBI
|
